Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer

被引：6

作者：

Zhang, Yalei ^{[1
,2
]}

Li, Ye ^{[2
]}

Chen, Kun ^{[1
,2
]}

Qian, Ling ^{[1
,2
]}

Wang, Peng ^{[1
,2
]}

机构：

[1] Fudan Univ, Dept Integrat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China

[2] Shanghai Med Coll, Fudan Univ, Dept Oncol, Shanghai, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2022年 / 18卷 / 05期

基金：

中国国家自然科学基金;

关键词：

Clinical trial; oncolytic virus; pancreatic cancer; tumor microenvironment; ENDOTHELIAL GROWTH-FACTOR; HSG-BINDING DOMAIN; PHASE-I; THERAPEUTIC AGENT; VIRUS THERAPY; ADENOVIRUS; ANGIOGENESIS; REPLICATION; GEMCITABINE; INJECTION;

D O I：

10.4103/jcrt.jcrt_91_21

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Emerging evidence has revealed the critical role of the tumor microenvironment (TME) in tumor progression, angiogenesis, metastasis, and immunosuppression. Oncolytic viruses (OVs), a versatile therapeutic agent that targets both cancer cells and the TME, have emerged as a promising candidate for antitumor therapy. Strategies of manipulating OVs against the TME include normalization of the tumor vasculature, decomposition of the tumor stroma, and reversion of the immunosuppressive microenvironment. In pancreatic cancer, desmoplastic stroma comprises up to 80% of the tumor mass, accompanied by hypovascularity and profound immunosuppression, conferring a particularly important role to TME-targeted oncolytic virotherapy. Mechanisms and supporting evidence of OVs reversing the tumor-privileged TME and applications of TME-targeted OVs for pancreatic cancer are summarized in this review.

引用

页码：1247 / 1255

页数：9

共 72 条

[1] EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis [J].

Agustoni, Francesco ;

Suda, Kenichi ;

Yu, Hui ;

Ren, Shengxiang ;

Rivard, Christopher J. ;

Ellison, Kim ;

Caldwell, Charles, Jr. ;

Rozeboom, Leslie ;

Brovsky, Kristine ;

Hirsch, Fred R. .

CANCER TREATMENT REVIEWS, 2019, 72 :15-27

[2] Pancreatic stellate cells in pancreatic cancer: In focus [J].

Allam, A. ;

Thomsen, A. R. ;

Gothwal, M. ;

Saha, D. ;

Maurer, J. ;

Brunner, T. B. .

PANCREATOLOGY, 2017, 17 (04) :514-522

[3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[4] Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer [J].

Angelova, Assia L. ;

Grekova, Svitlana P. ;

Heller, Anette ;

Kuhlmann, Olga ;

Soyka, Esther ;

Giese, Thomas ;

Aprahamian, Marc ;

Bour, Gaetan ;

Rueffer, Sven ;

Cziepluch, Celina ;

Daeffler, Laurent ;

Rommelaere, Jean ;

Werner, Jens ;

Raykov, Zahari ;

Giese, Nathalia A. .

JOURNAL OF VIROLOGY, 2014, 88 (10) :5263-5276

[5] Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer [J].

Bailey, Jennifer M. ;

Swanson, Benjamin J. ;

Hamada, Tomofumi ;

Eggers, John P. ;

Singh, Pankaj K. ;

Caffery, Thomas ;

Ouellette, Michel M. ;

Hollingsworth, Michael A. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :5995-6004

[6] Oncolytic Virotherapy and the Tumor Microenvironment [J].

Berkey, Sara E. ;

Thorne, Steve H. ;

Bartlett, David L. .

TUMOR IMMUNE MICROENVIRONMENT IN CANCER PROGRESSION AND CANCER THERAPY, 2017, 1036 :157-172

[7] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[8] Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer [J].

Carew, J. S. ;

Espitia, C. M. ;

Zhao, W. ;

Kelly, K. R. ;

Coffey, M. ;

Freeman, J. W. ;

Nawrocki, S. T. .

CELL DEATH & DISEASE, 2013, 4 :e728-e728

[9] Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer [J].

Carstens, Julienne L. ;

de Sampaio, Pedro Correa ;

Yang, Dalu ;

Barua, Souptik ;

Wang, Huamin ;

Rao, Arvind ;

Allison, James P. ;

LeBleu, Valerie S. ;

Kalluri, Raghu .

NATURE COMMUNICATIONS, 2017, 8

[10] A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer [J].

Chard, Louisa S. ;

Maniati, Eleni ;

Wang, Pengju ;

Zhang, Zhongxian ;

Gao, Dongling ;

Wang, Jiwei ;

Cao, Fengyu ;

Ahmed, Jahangir ;

El Khouri, Margueritte ;

Hughes, Jonathan ;

Wang, Shengdian ;

Li, Xiaozhu ;

Denes, Bela ;

Fodor, Istvan ;

Hagemann, Thorsten ;

Lemoine, Nicholas R. ;

Wang, Yaohe .

CLINICAL CANCER RESEARCH, 2015, 21 (02) :405-416

← 1 2 3 4 5 6 7 8 →